Clinical characteristics of non-sleepy obstructive sleep apnea patients: a study in a tertiary care sleep clinic in India
Monaldi Archives for Chest Disease · 2024
DOI: 10.4081/monaldi.2024.3031 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Monaldi Archives for Chest Disease, 2024. Verfasst von Ganesh Narwade und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Critical Care and Sleep, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Disorders of Excessive Somnolence, Obesity, Severity of Illness Index. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Obstructive sleep apnea (OSA) encompasses a diverse population, manifesting with or without symptoms of excessive daytime sleepiness. There is contention surrounding the significance of non-sleepy OSA within clinical contexts and whether routine treatment is warranted. This study aims to evaluate epidemiological and clinical distinctions between sleepy and non-sleepy OSA patients. A retrospective analysis was conducted on consecutive patients undergoing polysomnography for OSA assessment at tertiary care hospitals between 2018 and 2023. For 176 of 250 patients, complete polysomnography records with OSA diagnoses were available. Non-sleepy OSA was defined when a patient had an Epworth Sleepiness Scale score 50, neck circumference >40 cm, male gender) ≥3 for the non-sleepy OSA group was 87.7%, 89.3%, and 95.2% for any OSA severity, moderate to severe OSA, and severe OSA, respectively, while the corresponding sensitivity for the sleepy OSA group was 96.5%, 98.6%, and 100% for any OSA severity, moderate to severe OSA, and severe OSA, respectively. A novel symptom scoring tool, HASSUN, demonstrated a sensitivity of over 90% for all severity categories of OSA in both non-sleepy and sleepy OSA groups. The prevalence of cardiovascular and metabolic comorbidities did not significantly differ between non-sleepy and sleepy OSA patients. The physiological parameters, including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, arterial partial pressure of oxygen, and bicarbonate at baseline, were comparable between the two groups. To conclude, non-sleepy OSA patients are less obese, exhibit fewer symptoms, and have less severe OSA in comparison to sleepy OSA. Non-sleepy OSA patients display a similar likelihood of cardiovascular and metabolic comorbidities compared to sleepy OSA patients. Further investigations are warranted to elucidate the mechanisms underlying cardiovascular metabolic comorbidities in non-sleepy OSA patients. The proposed HASSUN scoring tool for non-sleepy OSA screening necessitates validation in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Critical Care and Sleep, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi.
ORCID-Profile: Ganesh Narwade, Manu Madan, Rohit Kumar, A J Mahendran, Nitesh Gupta
Zitieren
APA
Narwade, G., Madan, M., Kumar, R., Ish, P., Mahendran, A. J., Kaushik, R., & Gupta, N. (2024). Clinical characteristics of non-sleepy obstructive sleep apnea patients: a study in a tertiary care sleep clinic in India. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2024.3031
Vancouver
Narwade G, Madan M, Kumar R, Ish P, Mahendran AJ, Kaushik R, et al. Clinical characteristics of non-sleepy obstructive sleep apnea patients: a study in a tertiary care sleep clinic in India. Monaldi Archives for Chest Disease. 2024. doi:10.4081/monaldi.2024.3031
BibTeX
@article{Narwade2024,
author = {Narwade, Ganesh and Madan, Manu and Kumar, Rohit and Ish, Pranav and Mahendran, A J and Kaushik, Rajnish and Gupta, Nitesh},
title = {Clinical characteristics of non-sleepy obstructive sleep apnea patients: a study in a tertiary care sleep clinic in India},
journal = {Monaldi Archives for Chest Disease},
year = {2024},
doi = {10.4081/monaldi.2024.3031}
}
EUVIMED